{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:53:45Z","timestamp":1792158825569,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["2311520541"],"award-info":[{"award-number":["2311520541"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119402","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:34Z","timestamp":1791389134000},"page":"119402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Design, synthesis, and biological evaluation of 2-aminopyrimidine-5-carboxamide derivatives as potent selective Wee1 inhibitors"],"prefix":"10.1016","volume":"321","author":[{"given":"Fei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialong","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119402_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119402_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bjc.6604208","article-title":"G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer","volume":"98","author":"Bucher","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119402_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.drudis.2011.12.009","article-title":"Targeting the S and G2 checkpoint to treat cancer","volume":"17","author":"Chen","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119402_bib4","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.26062","article-title":"Wee1 kinase as a target for cancer therapy","volume":"12","author":"Do","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.119402_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting Wee1 kinase in cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119402_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A Wee1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Ror\u00e0","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119402_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbior.2013.04.001","article-title":"On the regulation of protein phosphatase 2A and its role in controlling entry into and exit from mitosis","volume":"53","author":"Hunt","year":"2013","journal-title":"Adv. Bio. Regul."},{"key":"10.1016\/j.ejmech.2026.119402_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of Wee1","volume":"2","author":"Aarts","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119402_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100495","article-title":"Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells, PLoS","volume":"9","author":"Kogiso","year":"2014","journal-title":"One"},{"key":"10.1016\/j.ejmech.2026.119402_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005120","article-title":"Integrated functional, gene expression and genomic analysis for the identification of cancer targets","volume":"4","author":"Iorns","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119402_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2014.07.102","article-title":"Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions","volume":"135","author":"Slipicevic","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119402_bib12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/1078-0432.CCR-19-0775","article-title":"Identification of therapeutic vulnerabilities in small-cell neuroendocrine prostate cancer","volume":"26","author":"Corella","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119402_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038254","article-title":"High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy","volume":"7","author":"Magnussen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119402_bib14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/leu.2011.392","article-title":"Integrated genomic analyses identify Wee1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia","volume":"26","author":"Porter","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119402_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11060-015-2050-4","article-title":"Expression and prognostic value of the Wee1 kinase in gliomas","volume":"127","author":"Music","year":"2016","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejmech.2026.119402_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1476-4598-13-72","article-title":"Integrated genomic analysis identifies the mitotic checkpoint kinase Wee1 as a novel therapeutic target in medulloblastoma","volume":"13","author":"Harris","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119402_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/jhep.2003.50112","article-title":"Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis","volume":"37","author":"Masaki","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.119402_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116804","article-title":"An update on small molecule compounds targeting synthetic lethality for cancer therapy","volume":"278","author":"Luo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119402_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","article-title":"A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors","volume":"41","author":"Falchook","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119402_bib20","article-title":"Targeting DNA damage and repair machinery via delivering Wee1 inhibitor and platinum (IV) prodrugs to stimulate STING pathway for maximizing chemo-immunotherapy in bladder cancer","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejmech.2026.119402_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102531","article-title":"Clinical development of Wee1 inhibitors in gynecological cancers: a systematic review","volume":"115","author":"Schutte","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.119402_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","article-title":"Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy","volume":"27","author":"Fu","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.119402_bib23","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.1021\/acs.jmedchem.1c01121","article-title":"Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer","volume":"64","author":"Huang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119402_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119402_bib25","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1021\/acs.jmedchem.3c02434","article-title":"Advanced design, synthesis, and evaluation of highly selective Wee1 inhibitors: enhancing pharmacokinetics and antitumor efficacy","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119402_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117312","article-title":"Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors","volume":"87","author":"Ye","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119402_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chembiol.2019.10.013","article-title":"Development and characterization of a Wee1 kinase degrader","volume":"27","author":"Li","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119402_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128636","article-title":"Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases","volume":"64","author":"Aublette","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119402_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"Wee1 inhibitor: clinical development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.119402_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/acsmedchemlett.2c00481","article-title":"Selective Wee1 inhibitors led to antitumor activity in vitro and correlated with myelosuppression","volume":"14","author":"Guler","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119402_bib31","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1021\/acschembio.6b00466","article-title":"A Wee1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single agent cytotoxicity in medulloblastoma cells","volume":"11","author":"Matheson","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"7_Supplement","key":"10.1016\/j.ejmech.2026.119402_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-3091","article-title":"Discovery and development of a potent and highly selective Wee1 inhibitor IMP7068","volume":"83","author":"Cai","year":"2023","journal-title":"Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:23:06Z","timestamp":1792156986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":32,"alternative-id":["S0223523426008470"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119402","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of 2-aminopyrimidine-5-carboxamide derivatives as potent selective Wee1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119402"}}